Clifford Chance
Clifford Chance advises SciClone Pharmaceuticals on its Hong Kong IPO and Listing
3 March 2021
- Christine Xu, Liu Fang, Samson Chan, Erxin Lu, , Tao Yang, ,
- Hong Kong, Shanghai
Clifford Chance advises SciClone Pharmaceuticals on its Hong Kong IPO and Listing
Leading international law firm Clifford Chance has advised SciClone Pharmaceuticals (Holdings) Limited on its US$281 million initial public offering and listing on the main board of the Hong Kong Stock Exchange.
The Shanghai-based biopharmaceutical company is focused on some of the largest and fastest growing therapeutic areas such as oncology and severe infection. The joint sponsors on the deal are Morgan Stanley, CICC and Credit Suisse.
Partners Christine Xu and Liu Fang co-led on the deal, with support from a team which includes senior associates Samson Chan and Erxin Lu, associates Alex Feng, Tao Yang, Zhengyuan Fan and Liying Liang, and trainee Astrid Zhuang.
Christine said, "We are honoured to have the opportunity to work with SciClone toward achieving another milestone. This deal is also a testament of our market-leading expertise in the healthcare and biotech sector."
Clifford Chance's market leading Greater China IPO practice continues to advise on the equity fundraising of the most innovative biotech and pharmaceutical companies, including Harbour BioMed, Hygeia Healthcare and Genetron.
高伟绅助力赛生药业首次公开发行和香港上市
国际领先律师事务所高伟绅为赛生药业控股有限公司2.81亿美元首次公开发行和香港联合交易所主板上市提供法律服务。
赛生药业是一家总部位于上海的生物制药公司，专注于肿瘤和严重感染等最大且发展迅速的治疗领域。本次上市交易的联席保荐人为摩根士丹利、中金公司和瑞信。
本项目由合伙人许文嘉和方刘共同牵头，团队成员包括陈澍森、陆尔馨、冯也威、杨弢、樊征远、梁莉颖以及庄立平。
许文嘉律师表示：“我们很荣幸能有机会与赛生药业合作，助力赛生药业实现企业发展的另一个里程碑。这一项目也彰显了高伟绅在医疗保健和生物技术领域的经验和优势。”
高伟绅市场领先的大中华区上市业务团队曾参与众多创新生物科技和制药企业的股权资本市场业务，包括和铂医药、海吉亚医疗以及泛生子。
